R-mabHD + ABVD

Phase 2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hodgkin's Disease

Conditions

Hodgkin's Disease

Trial Timeline

Jul 1, 2011 → Apr 1, 2014

NCT ID

NCT00797472

About R-mabHD + ABVD

R-mabHD + ABVD is a phase 2 stage product being developed by Eli Lilly for Hodgkin's Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT00797472. Target conditions include Hodgkin's Disease.

What happened to similar drugs?

8 of 20 similar drugs in Hodgkin's Disease were approved

Approved (8) Terminated (2) Active (10)

✅Chemotherapy + Immunochemotherapy + PegfilgrastimRocheApproved

✅rituximab [MabThera/Rituxan]RocheApproved

✅TenofovirGilead SciencesApproved

✅temsirolimus + temsirolimusPfizerApproved

✅Kepivance (Palifermin)Swedish Orphan BiovitrumApproved

✅Entecavir prophylaxis + Therapeutic entecavirBristol Myers SquibbApproved

✅Granulocyte-colony stimulating factor (G-CSF) + Fixed Dose Plerixafor + Weight-Based PlerixaforSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00797472	Phase 2	UNKNOWN	Jul 1, 2011	Apr 1, 2014	Hodgkin's Disease

Competing Products

20 competing products in Hodgkin's Disease

See all competitors

Product	Company	Stage	Hype Score
YM155 + Rituximab	Astellas Pharma	Phase 2	35
Tazemetostat	Eisai	Phase 2	35
ONTAK	Eisai	Phase 2	35
Tazemetostat	Eisai	Phase 1	29
ME-401	Kyowa Kirin	Phase 1	29
ME-401	Kyowa Kirin	Phase 2	39
Nivolumab + Brentuximab vedotin	Ono Pharmaceutical	Phase 3	32
R-mabHDI and ABVD + ABVD	Eli Lilly	Phase 3	36
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + Gemcitabine	Eli Lilly	Phase 1/2	32
gemcitabine	Eli Lilly	Phase 2	27
gemcitabine + cisplatin + dexamethasone	Eli Lilly	Phase 2	35
LY317615	Eli Lilly	Phase 2	35
LY4584180 + Rituximab	Eli Lilly	Phase 1	36
Bortezomib + Rituximab + Rituximab	Johnson & Johnson	Phase 3	40
HRS-3738	Jiangsu Hengrui Medicine	Phase 1	25
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin	Jiangsu Hengrui Medicine	Phase 2	31
ABT-199 + Ketoconazole	AbbVie	Phase 1	29
ABT-199 + Rifampin	AbbVie	Phase 1	21
[14C]ABT-199 (GDC-0199)	AbbVie	Phase 1	21
ABT-199 + Rituximab + Bendamustine	AbbVie	Phase 1	29